Chronic graft-versus-host disease (CGVHD)
Clinical trials for Chronic graft-versus-host disease (CGVHD) explained in plain language.
Never miss a new study
Get alerted when new Chronic graft-versus-host disease (CGVHD) trials appear
Sign up with your email to follow new studies for Chronic graft-versus-host disease (CGVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for GVHD patients: ruxolitinib tested as First-Line therapy
Disease control Recruiting nowThis study compares two drugs, ruxolitinib and prednisone, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication after bone marrow transplant. About 120 adults who need systemic therapy for cGVHD will be randomly assigned to receive one of the two d…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug vimseltinib aims to tame chronic GVHD in failed treatments
Disease control Recruiting nowThis study tests whether the drug vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD) who have not improved after at least two prior treatments. About 48 participants will take vimseltinib daily for up to two years. The g…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Phase 2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC